Comparing the efficacy of naltrexone implant plus cognitive behavioural therapy (CBT) versus CBT alone for the treatment of methamphetamine (MA) use disorders. The primary outcome is return to use measured by urine drug screen (UDS) and self-reported MA use. Given the lack of available pharmacotherapy for MA use disorders, research into its treatment is pivotal in moving forward to reduce the burden of MA in Australia

Principal investigator

Alexander Gallo
Magnifying glass

Area of science


Systems used


Applications used
Partner Institution: The University of Western Australia| Project Code: AL-1423

The Challenge

MA use in Australia is an ever increasing problem with no approved pharmacotherapies. We aim to reduce this burden by offering pharmacotherapies to these patients.

The Solution

Clinical trial comparing the efficacy of naltrexone plus CBT versus CBT alone

The Outcome

Pawsey servers give us the ability to store the data for this project.